Alembic to expand their U.S. commercial portfolio with FDA-approved PIVYA for the treatment of women with uncomplicated ...

Vaginal microbiome-drug interactions affect antibiotic treatment for bacterial vaginosis, emphasizing the need for ...

Iterum Therapeutics plc (Nasdaq: ITRM) ('Iterum” or the 'Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant ...

As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...

An international research team led by the Helmholtz Center for Infection Research (HZI) has discovered a new strategy used by ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...

Microplastics aren’t just everywhere — they might be turning your dinner into a breeding ground for supercharged pathogens.

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...

Wockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions in the US and India. The company is exploring out-licensing ...

(“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment ...

Background In 2011, there were approximately two million cases of hospital-acquired infections in the United States, more than 75,000 of which were fatal. [1] Gram-negative bacteria cause the four ...